Ariadne Diagnostics, LLC (Ariadne-Dx) is a diagnostic discovery and development company that utilizes integrated bioinformatics tools to identify novel biomarker panels for the advancement of prognostic and predictive tests in areas of unmet medical need. The company does not confine itself to the use of specific diagnostic platforms and employs modern genomic, proteomic and metabolomic tools in its diagnostic development, often incorporating biomarkers at the DNA, RNA and protein levels simultaneously to create its diagnostic panels.
Internal research and development at Ariadne-Dx is primarily focused on the development of companion diagnostics (CDx) for both cancer and neuromuscular/neurodegenerative disorders.
Role within Neuromics
Identify functional pathways, potential biomarkers and data outflow integration.
Develop in silico models for development of appropriate preventive or therapeutic personalized interventions.
Workpackage 10 - Elucidation of pathogenesis and monitoring of treatment
Workpackage 11 - Modifier gene identification, prioritization and study
Workpackage 2 - Identification of novel disease genes in NDD/NMD patients
Workpackage 3 - Identification of modifying factors in cohorts enriched by deep phenotyping
Workpackage 4 - Identification of hypothesis-driven biomarkers for disease progression
Workpackage 6 - Diagnostic read outs for predicting disease modification